ArticleBMC cancer2025
Prognostic value of thrombocytosis in nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThrombocytosis, recognized as a clinically significant event, has been established as an unfavorable prognostic factor in various solid tumors. This study aimed to investigate the prognostic value of thrombocytosis-occurring either before or during treatment-in patients with non-metastatic nasopharyngeal carcinoma (NPC) who received intensity-modulated radiotherapy (IMRT).
methodsA total of 203 patients with NPC who received IMRT were retrospectively analyzed. Thrombocytosis was defined as a platelet count exceeding 300 × 10⁹/L. The prognostic significance of thrombocytosis was assessed using the log-rank test and multivariate analyses.
resultsAmong the 203 patients, 42 cases (20.7%) exhibited thrombocytosis prior to treatment initiation, and 81 cases (39.9%) developed thrombocytosis during therapy. Patients with thrombocytosis had more advanced N stage compared to those without (48.8% vs. 30.0%; P = 0.008). The 5-year progression-free survival (PFS) rate was significantly lower in patients with thrombocytosis than in those without (78.3% vs. 89.1%; P = 0.019). Multivariate analyses revealed that thrombocytosis was an independent prognostic factor for inferior PFS (hazard ratio [HR] = 2.37, 95% confidence interval [CI] = 1.08-5.21; P = 0.032). A similar result was observed in the subgroup of patients who received induction chemotherapy with the TP regimen (HR = 2.88, 95% CI = 1.12-7.36; P = 0.028).
conclusionsThrombocytosis occurring before or during treatment serves as a valuable predictor of disease progression and poor prognosis in patients with NPC. Patients presenting with thrombocytosis may require more intensive therapeutic strategies; therefore, the presence of thrombocytosis should be considered when selecting an induction chemotherapy regimen. Further prospective studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.